GLG News by Adderall XR Prescribers (US)
Articles with lock require a subscription to GLG News |
Request a free trial
March 19, 2008Another New FDA Indication For Abilify
Analysis of: U.S. Food and Drug Administration Approves Abilify (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) | pharmalive.com
Author: Louis Sanfilippo, President, LCS Group, LLC
The FDA’s approval of Abilify for treatment of acute manic and mixed episodes of pediatric Bipolar Disorder is a very important milestone. Treatment with Abilify already has had growing off-label use in the pediatric population, in both acute and chronic settings, because of its favorable...
March 7, 2008
Exciting new treatment for OCD and Social Anxiety Disorder
Analysis of: FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder | pharmalive.com
Author: GLG Expert Contributor
Exciting new treatment for OCD and Social Anxiety DisorderAnalysis of: FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder | pharmalive.com
Author: GLG Expert Contributor
1. Controlled release preparations are often better tolerated with fewer side effects than immediate release preparations 2. OCD and SAD are severe, highly prevalent and chronically disabling conditions 3. Despite presence of SSRIs and other treatment, e.g, cognitive behavioral therapy, up to 1/3 of...
March 7, 2008
FDA Approval of Abilify for Pediatric Bipolar disorder is a Major Advance
Analysis of: U.S. Food and Drug Administration Approves Abilify (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) | pharmalive.com
Author: GLG Expert Contributor
FDA Approval of Abilify for Pediatric Bipolar disorder is a Major AdvanceAnalysis of: U.S. Food and Drug Administration Approves Abilify (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) | pharmalive.com
Author: GLG Expert Contributor
1. Despite common use of multiple psychotropic medications for bipolar disorder in youth, there are few FDA-approved treatments 2. Abilify is one of the safest and best tolerated of the atypical antipsychotics with fewer side effects than some of the other atypical antipsychotic medications 3. This...
March 6, 2008Dov’s Triple Reuptake Inhibitor Enters Phase II Major Depression Trial
Analysis of: DOV Pharmaceutical, Inc. Initiates Phase II Clinical Trial in Patients With Major Depressive Disorder | www.pipelinereview.com
Author: Louis Sanfilippo, President, LCS Group, LLC
Triple-reuptake inhibitors (TRIs) represent an emerging class of antidepressant drugs in development with potential application for other disorders including ADHD and obesity. By potentiating all three of the main monoamine neurotransmitters implicated in depression - serotonin, norepinephrine,...
March 6, 2008
FDA approval of Luvox CR is good news for psychiatrists!
Analysis of: FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder | pharmalive.com
Author: GLG Expert Contributor
FDA approval of Luvox CR is good news for psychiatrists!Analysis of: FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder | pharmalive.com
Author: GLG Expert Contributor
Luvox was one of the first SSRI's approved for pediatric prescription (for OCD rather than for depression). When patent expired, the maker discontinued manufacture. It has been available in limited supply as generic. Availability of brand-name extended-release product (Luvox CR) will be a significant...
March 5, 2008
Influenza Vaccine May Get Much Needed Boost
Analysis of: Intercell completes Phase I clinical trial for improved seasonal Flu vaccine formulated with IC31(R) | www.pipelinereview.com
Author: GLG Expert Contributor
Influenza Vaccine May Get Much Needed BoostAnalysis of: Intercell completes Phase I clinical trial for improved seasonal Flu vaccine formulated with IC31(R) | www.pipelinereview.com
Author: GLG Expert Contributor
Intercell's IC31 may provide a much needed improved immune response to influenza vaccine. Considering the relatively poor response to this year's influenza vaccine, if Intercell can demonstrate continued superior immune response and clinical efficacy, IC31 may find a home in the influenza vaccine...
March 5, 2008An Uphill Battle Ahead – Luvox CR Approved for OCD and Social Anxiety
Analysis of: FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder | pharmalive.com
Author: Louis Sanfilippo, President, LCS Group, LLC
Fluvoxamine, the least known of the selective serotonin reuptake inhibitors in the US, will now have an FDA approved controlled release version - Luvox CR - for the treatment of OCD and Social Anxiety Disorder. The collaboration between Jazz Pharmaceuticals and Solvay will have only an uphill...
March 4, 2008Deep Brain Stimulation for Treatment Resistant Depression – The Race is On
Analysis of: St. Jude Medical Announces Clinical Study of Deep Brain Stimulation for Depression | www.pipelinereview.com
Author: Louis Sanfilippo, President, LCS Group, LLC
Deep brain stimulation (DBS), an FDA approved device treatment for Parkinson’s Disease and essential tremor, has demonstrated quite remarkable findings in several very small pilot studies for treatment resistant depression. There is great hope among the device makers – namely Medtronics...
February 29, 2008
Acne Care Remains True to Form
Analysis of: What Skin Care Routines and Treatments Are Effective for Adolescent Acne? | www.medscape.com
Author: GLG Expert Contributor
Acne Care Remains True to FormAnalysis of: What Skin Care Routines and Treatments Are Effective for Adolescent Acne? | www.medscape.com
Author: GLG Expert Contributor
This excellent review of acne treatments shows that we still rely on the basics for acne treatment: benzoyl peroxide, topical antibiotics, and retinoids.
February 27, 2008MEM 3454, A Hopeful New Drug Treatment for Cognitive Impairment in Schizophrenia?
Analysis of: Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia | www.pipelinereview.com
Author: Louis Sanfilippo, President, LCS Group, LLC
The announcement of this small biomarker study for MEM 3454, an alpha-7 neuronal nicotinic receptor (NNR) partial agonist in joint development by Memory Pharmaceuticals and Roche for the treatment of cognitive impairment associated with schizophrenia (CIAS), seems like a step in the right direction...
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 Next31 to 40 of 215
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
How a Drug Maker Tries to Outwit Generics
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008